U.S. Markets closed

Medifirst Solutions Announces New Division for CBD Products

Freehold, NJ, Oct. 29, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- MEDIFIRST SOLUTIONS, INC. (MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device and Specialty Pharmacy Drug Consulting Services is pleased to announce a company update.

Medifirst is pleased to announce that it is launching a division for CBD sales and products. There is already an explosive demand for CBD products, including healthcare and medical products, beverages and edibles, and pet products. CBD usage is surging in the United States as awareness and access to CBD products rapidly expands. CBD oil is gaining momentum with studies confirming that it may help treat a variety of ailments and conditions, such as pain, anxiety, stress, depression, cancer related symptoms, and weight loss.

The Brightfield Group recently announced projections for the hemp CBD industry to become a $5.7 billion market by next year, with a projection of nearly 400% growth to $22 billion by 2022. Hemp is variety of the cannabis plants. It does not contain any legally significant quantities of tetrahydrocannabinol (THC), the chemical that produces a high in marijuana. It does contain the active ingredient cannabidiol (CBD), which has been widely reported and shown to have great medicinal value - reports that now have been substantiated by the U.S. Food and Drug Administration. There has been a strong movement to make CBD products legal in all 50 states.

Today, Medifirst President Bruce J. Schoengood, stated that “CDB products are a great complement to our FDA cleared Time Machine Therapeutic Laser for all-natural pain relief, and there is a tremendous demand for CBD products. Through our existing healthcare relationships, we have strong interest from oversea markets for China, Japan, and the Asia-Pacific region as well as in the U. S. market. Medifirst is working on completing related contracts and agreements and anticipates a formal announcement in the upcoming days or weeks.”

Medifirst recently announced it was presenting the Time Machine Laser to the Antah HealthCare Group, one of the largest medical device distributors in Malaysia. Medifirst President, Bruce J. Schoengood, stated that, “We are very pleased to report that initial testing results are positive and Medifirst representatives are meeting with Antah representatives in Hong Kong to discuss possible distribution structures and various possible business models with regards to working with Antah Healthcare. While we can make no assurances of a final agreement, we are optimistic since they are satisfied with the results. We anticipate further updates in the upcoming days and weeks.”

About CCRx

CCRx services of specialty drug pharmacy consulting and revenue stream management utilize over 60 years of combined specialty pharmacy and infusion therapy experience. The services are designed to increase profits for pharmacies.  Services include: clinical review, expedited medical insurance verification, training for drug dispensing, insurance billing, collections, and reconciliation. The billing services will address any denials and include appeals and resubmissions. The division will provide key services to undervalued clients by securing reimbursement of overlooked revenue within the ever-expanding market of the specialty pharmacy market in today's healthcare system.  We believe that specialty drugs (often described as prescription drugs that are difficult to manufacture and require special handling or administration, have limited distribution, target a narrow group of chronic diseases, are costly, and require ongoing clinical support), will drive nearly all the pharmaceutical industry’s market growth from 2015–2020.

About The Time Machine Laser

Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions.  The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. Visit www.medifirstsolutions.com for more information. Follow on Twitter @Medi_First and for Facebook visit Medifirst Solutions.

Forward-Looking Statements:  

The statements in this press release that relate to the company’s expectations about the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

Contact:   Investor Relations
Phone:  (732) 786-8044
Email:  admin@medifirstsolutions.com
Website:   www.medifirstsolutions.com